ReviewCureus2025
Cervical Disc Arthroplasty for Isolated One-Level Degenerative Spine Disease: A Comprehensive Review of the Current Trends.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical myelopathy is a debilitating degenerative condition caused by spinal cord compression, which may affect multiple levels of the cervical spinal cord. It frequently necessitates surgical intervention when conservative treatment fails. While anterior cervical discectomy and fusion (ACDF) has long been the standard procedure, cervical disc arthroplasty (CDA) has emerged as a viable alternative, particularly for patients with isolated one-level disease. This comprehensive review, according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, synthesizes current literature evaluating the safety, efficacy, and biomechanical advantages of CDA in treating isolated one-level cervical myelopathy and/or radiculopathy. Evidence from current scientific papers demonstrates that CDA provides comparable neurological improvement to ACDF, since the process of decompressing is the same for both of them, while offering superior motion preservation, reduced rates of adjacent segment degeneration (ASD), and lower reoperation rates. Patient selection remains critical, with radiological and clinical criteria guiding candidacy for CDA. Technological advances, including 3D-printed implants and robotic-assisted surgery, are further enhancing outcomes and expanding indications. As long-term data accumulate continuously, CDA is increasingly supported as an effective, motion-preserving option for appropriately selected patients with single-level cervical myelopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.